These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

514 related items for PubMed ID: 20929915

  • 21. Comparison of Iron Dosing Strategies in Patients Undergoing Long-Term Hemodialysis: A Randomized Controlled Trial.
    Bielesz B, Lorenz M, Monteforte R, Prikoszovich T, Gabriel M, Wolzt M, Gleiss A, Hörl WH, Sunder-Plassmann G.
    Clin J Am Soc Nephrol; 2021 Oct; 16(10):1512-1521. PubMed ID: 34470831
    [Abstract] [Full Text] [Related]

  • 22. Safety and Efficacy of Ferric Carboxymaltose in the Treatment of Iron Deficiency Anaemia in Patients with Inflammatory Bowel Disease, in Routine Daily Practice.
    Stein J, Aksan A, Klemm W, Nip K, Weber-Mangal S, Dignass A.
    J Crohns Colitis; 2018 Jun 28; 12(7):826-834. PubMed ID: 29955835
    [Abstract] [Full Text] [Related]

  • 23. Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy.
    Hedenus M, Karlsson T, Ludwig H, Rzychon B, Felder M, Roubert B, Birgegård G.
    Med Oncol; 2014 Dec 28; 31(12):302. PubMed ID: 25373320
    [Abstract] [Full Text] [Related]

  • 24. Intravenous versus oral iron for anaemia among pregnant women in Nigeria (IVON): an open-label, randomised controlled trial.
    Afolabi BB, Babah OA, Adeyemo TA, Balogun M, Banke-Thomas A, Abioye AI, Akinajo OR, Galadanci HS, Quao RA, Adelabu H, Sam-Agudu NA, Adaramoye VO, Abubakar A, Banigbe B, Olorunfemi G, Beňová L, Larsson EC, Annerstedt KS, Hanson C, Thornton J, IVON Trial Investigators.
    Lancet Glob Health; 2024 Oct 28; 12(10):e1649-e1659. PubMed ID: 39304237
    [Abstract] [Full Text] [Related]

  • 25. Hepcidin Response to Iron Therapy in Patients with Non-Dialysis Dependent CKD: An Analysis of the FIND-CKD Trial.
    Gaillard CA, Bock AH, Carrera F, Eckardt KU, Van Wyck DB, Bansal SS, Cronin M, Meier Y, Larroque S, Roger SD, Macdougall IC.
    PLoS One; 2016 Oct 28; 11(6):e0157063. PubMed ID: 27276035
    [Abstract] [Full Text] [Related]

  • 26. Randomized Controlled Trial of Intravenous Ferric Carboxymaltose vs Oral Iron to Treat Iron Deficiency Anemia After Variceal Bleed in Patients With Cirrhosis.
    Tabish M, Agarwal S, Gopi S, Rana R, Ahmed S, Gunjan D, Sharma S, Saraya A.
    Am J Gastroenterol; 2024 Oct 01; 119(10):2061-2069. PubMed ID: 38517084
    [Abstract] [Full Text] [Related]

  • 27. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
    Geisser P, Banké-Bochita J.
    Arzneimittelforschung; 2010 Oct 01; 60(6a):362-72. PubMed ID: 20648928
    [Abstract] [Full Text] [Related]

  • 28. Intravenous ferric carboxymaltose is effective and safe in patients with inflammatory rheumatic diseases.
    Salvadori U, Vittadello F, Al-Khaffaf A, Maier A, Cappelletto PC, Daves M, Raffeiner B.
    Blood Transfus; 2020 May 01; 18(3):176-181. PubMed ID: 31855154
    [Abstract] [Full Text] [Related]

  • 29. Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder.
    Geisser P, Rumyantsev V.
    Arzneimittelforschung; 2010 May 01; 60(6a):373-85. PubMed ID: 20648929
    [Abstract] [Full Text] [Related]

  • 30. [Efficacy and tolerability of ferric carboxymaltose in geriatric patients with anemia. Data from three non-interventional studies].
    Röhrig G, Steinmetz T, Stein J, Geisel T, Virgin G, Schaefer R, Bach M, Schulz RJ.
    MMW Fortschr Med; 2014 Jul 24; 156 Suppl 2():48-53. PubMed ID: 25351027
    [Abstract] [Full Text] [Related]

  • 31. Randomized clinical trial of preoperative oral versus intravenous iron in anaemic patients with colorectal cancer.
    Keeler BD, Simpson JA, Ng O, Padmanabhan H, Brookes MJ, Acheson AG, IVICA Trial Group.
    Br J Surg; 2017 Feb 24; 104(3):214-221. PubMed ID: 28092401
    [Abstract] [Full Text] [Related]

  • 32. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial.
    Onken JE, Bregman DB, Harrington RA, Morris D, Buerkert J, Hamerski D, Iftikhar H, Mangoo-Karim R, Martin ER, Martinez CO, Newman GE, Qunibi WY, Ross DL, Singh B, Smith MT, Butcher A, Koch TA, Goodnough LT.
    Nephrol Dial Transplant; 2014 Apr 24; 29(4):833-42. PubMed ID: 23963731
    [Abstract] [Full Text] [Related]

  • 33. Randomized trial comparing ferric carboxymaltose vs oral ferrous glycine sulphate for postoperative anaemia after total knee arthroplasty.
    Bisbe E, Moltó L, Arroyo R, Muniesa JM, Tejero M.
    Br J Anaesth; 2014 Sep 24; 113(3):402-9. PubMed ID: 24780615
    [Abstract] [Full Text] [Related]

  • 34. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial.
    Van Wyck DB, Martens MG, Seid MH, Baker JB, Mangione A.
    Obstet Gynecol; 2007 Aug 24; 110(2 Pt 1):267-78. PubMed ID: 17666600
    [Abstract] [Full Text] [Related]

  • 35. TREATMENT OF ANEMIA AND IMPROVEMENT OF QUALITY OF LIFE AMONG PATIENTS WITH CROHN'S DISEASE: experience using ferric carboxymaltose.
    Sobrado CW, Cançado RD, Sobrado LF, Frugis MO, Sobrado MF.
    Arq Gastroenterol; 2015 Dec 24; 52(4):255-9. PubMed ID: 26840464
    [Abstract] [Full Text] [Related]

  • 36. Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials.
    Wolf M, Rubin J, Achebe M, Econs MJ, Peacock M, Imel EA, Thomsen LL, Carpenter TO, Weber T, Brandenburg V, Zoller H.
    JAMA; 2020 Feb 04; 323(5):432-443. PubMed ID: 32016310
    [Abstract] [Full Text] [Related]

  • 37. Use of intravenous iron supplementation in chronic kidney disease: an update.
    Macdougall IC, Geisser P.
    Iran J Kidney Dis; 2013 Jan 04; 7(1):9-22. PubMed ID: 23314137
    [Abstract] [Full Text] [Related]

  • 38. Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient: oral or intravenous?
    Macdougall IC.
    Curr Med Res Opin; 2010 Feb 04; 26(2):473-82. PubMed ID: 20014980
    [Abstract] [Full Text] [Related]

  • 39. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial.
    Ponikowski P, Kirwan BA, Anker SD, McDonagh T, Dorobantu M, Drozdz J, Fabien V, Filippatos G, Göhring UM, Keren A, Khintibidze I, Kragten H, Martinez FA, Metra M, Milicic D, Nicolau JC, Ohlsson M, Parkhomenko A, Pascual-Figal DA, Ruschitzka F, Sim D, Skouri H, van der Meer P, Lewis BS, Comin-Colet J, von Haehling S, Cohen-Solal A, Danchin N, Doehner W, Dargie HJ, Motro M, Butler J, Friede T, Jensen KH, Pocock S, Jankowska EA, AFFIRM-AHF investigators.
    Lancet; 2020 Dec 12; 396(10266):1895-1904. PubMed ID: 33197395
    [Abstract] [Full Text] [Related]

  • 40. The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study.
    Ponikowski P, Filippatos G, Colet JC, Willenheimer R, Dickstein K, Lüscher T, Gaudesius G, von Eisenhart Rothe B, Mori C, Greenlaw N, Ford I, Macdougall I, Anker SD, FAIR-HF Trial Investigators.
    Eur J Heart Fail; 2015 Mar 12; 17(3):329-39. PubMed ID: 25683972
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.